Business
Appointment of Chief Commercial Officer
Appointment of Chief Commercial Officer.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n \n \n\n \n05 September, 2024\n \nEDX Medical Group plc\n \nAQSE: EDX\n(\"EDX Medical\" or the \"Company\")\n \n APPOINTMENT OF CHIEF COMMERCIAL OFFICER\n \nCAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today the appointment of Eric Vick as Chief Commercial Officer.\n \nThe appointment follows the successful completion of several key commercial agreements which enable the Company to develop and market a range of innovative diagnostic products and services in the UK and key European countries.\n \nEDX Medical will launch a portfolio of clinical diagnostic products and services, including:\n \n· The world's most comprehensive molecular profiling solutions, which enable physicians to make more precise and individualised cancer treatment decisions. EDX Medical is the exclusive distributor in the UK of these innovative tests, developed by Caris Life Sciences, a leading US-based next-generation AI TechBio and precision medicine company.\n \n· The cResponse™ 'functional' cancer assay. It will be distributed in the UK, Sweden, Finland, Norway and Denmark. cResponse™, developed by Curesponse Ltd., assesses how an individual patient's living tumour tissue responds to selected medicines, identifying the most effective treatment options. There are almost 600,000 newly diagnosed solid tumour cases annually in these markets.\n \n· Comprehensive hereditary genetic risk testing products and services, for cancer and heart disease. The tests will be supplied initially in the UK through private healthcare providers and via specific NHS Genetic and Genomic Testing Centres. Within the UK alone, an estimated 2.5 million individuals are considered eligible for hereditary cancer and cardiac scr...